Skip to content
Search

Latest Stories

Coolie No.1 won’t get a simultaneous release in single screens

Murtuza Iqbal

Varun Dhawan and Sara Ali Khan starrer Coolie No. 1 is all set to release on Amazon Prime Video on 25th December 2020. A couple of weeks ago, there were reports that the film might simultaneously release in single screens in India.


However, now, according to a report in Bollywood Hungama, the film won’t be releasing in single screens and will only stream on the OTT platform.

A source told the portal, “The multiplexes were never in favour of a simultaneous release in OTT as well as in cinemas. However, the single-screen cinema owners had no qualms with this arrangement. They believed that their target audience did not have access to the streaming giant and would be more than happy to see Coolie No. 1 in cinemas. Hence, a discussion was initiated between the exhibitors, Varun Dhawan, director David Dhawan, producer Vashu Bhagnani, and Amazon Prime. Amazon heard out their request for a hybrid release and assured that they would come back with their answer.”

“But after a few days, the Amazon Prime team put their foot down and made it amply clear that they would want the film to be available exclusively on their platform. They had a justification behind this decision since the Amazon team had paid a decent sum for Coolie No. 1’s OTT premiere. Therefore they were not in consensus for sharing the movie theatrically and hence, ruled out the possibility of its theatrical release. The makers tried to persuade them, however, they didn’t relent. Needless to say, the makers as well as the single screen owners are miffed and disappointed with this decision,” added the source.

Directed by David Dhawan, the movie is a remake of the 1995 release Coolie No.1 which starred Govinda and Karisma Kapoor in the lead roles.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less